# HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation

> **NCT05263453** · PHASE2 · UNKNOWN · sponsor: **Shanghai Kechow Pharma, Inc.** · enrollment: 104 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** HL-085
- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT05263453
- **Lead sponsor:** Shanghai Kechow Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-06
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2023-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05263453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05263453, "HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05263453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*